ReviewFrontiers in immunology2026
Non-histone lactylation in cancer: current advances and clinical implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactylation, a novel post-translational modification characterized by the covalent attachment of lactate to specific lysine residues, has emerged as a critical metabolic regulator in cancer. Initially linked to histone modification-mediated transcriptional control, recent advancements have expanded this paradigm by revealing widespread non-histone lactylation, which modulates protein stability, enzymatic activity, and interactions, thereby significantly impacting tumor proliferation, metastasis, and therapy resistance. Recent advances have uncovered several key enzymes driving lactylation, including lysine acetyltransferases and deacetylases, and novel "writers" like alanyl-tRNA synthetases, highlighting the complexity and diversity of lactylation mechanisms. This review synthesizes current advances in non-histone lactylation in cancer, emphasizing its regulatory mechanisms and functional impacts. We also discuss potential therapeutic strategies, such as small-molecule inhibitors and peptides targeting lactate-driven pathways. By integrating current evidence, this review underscores non-histone lactylation as a promising area for cancer research and management, offering new insights into the complex interplay between metabolism and tumor biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.